Cardiogenic Shock Intravascular Cooling Trial (CHILL-SHOCK)

Background : Cardiogenic shock (CS) is complicated by high mortality. Targeted temperature control (TTC) has been proposed as an adjunct therapy in CS. This study aims to examine the safety of TTC in patients presenting with CS. Methods and Results : In this open label, randomized controlled pilot trial, 20 patients with hemodynamic criteria for CS were assigned to standard of care plus TTC vs. standard of care alone. The primary outcome was a composite safety outcome including well described complications of TTC. Secondary outcomes included mortality at 90 days, invasive hemodynamic and echocardiographic parameters, electrocardiographic measurements, and inotrope dosing. There were no significant differences in the composite analysis of prespecified safety outcomes (3 events in TTC group vs 0 events in control group, p = 0.24). Patients randomized to TTC demonstrated a statistically significant increase in cardiac index and cardiac power index compared to the control group at 48-96 hours after randomization (3.6 [3.1, 3.9] L/min/m2 vs 2.6 [2.5, 3.15] L/min/m2, p = 0.029 and 0.61 [0.55, 0.7] W/m2 vs 0.53 [0.435, 0.565] W/m2, p = 0.029, respectively). Conclusion : TTC may be a safe adjunct therapy for patients presenting with CS and may yield improvement in specific hemodynamic parameters.